Long-term follow-up:: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression
Long-term follow-up:: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression
复制标题
DOI：
10.1016/s0264-410x(02)00102-0
复制
发表时间：
2002-05-22
期刊：
影响因子：
5.5
通讯作者：
Coutinho, RA
中科院分区：
文献类型：
--
作者：
Lindenburg, CEA;Stolte, I;Coutinho, RA
在一项多中心队列研究中，研究了人类免疫缺陷病毒（HIV）-1感染者接受HIV-1 p17/p24：Ty病毒样颗粒（p24-VLP）治疗性疫苗接种对进展为AIDS、死亡、CD 4细胞计数小于或等于200个/mm 3和CD 4细胞计数下降的长期影响。56名受试者参加了1993年p24-VLP治疗的11期双盲安慰剂对照试验。使用考克斯比例风险分析，发现疫苗组和安慰剂组在进展至死亡方面无差异（调整后的风险率（HR）：0.68）（95% CI：0.05-7.83），艾滋病（校正HR：1.07（95%CI：0.21-5.36））和CD 4细胞计数小于或等于200个细胞/mm（3）（校正HR：1.00（95%CI：0.35-2.87））。使用线性回归校正一个人内的多次访问，没有发现疫苗接种对CD 4细胞计数下降的影响，调整抗逆转录病毒治疗（ART）的使用（P = 0.98）。总之，p24-VLP治疗性疫苗接种与HIV-1疾病进展缓慢无关。(C)2002爱思唯尔科技有限公司。保留所有权利。
Long-term effects of therapeutic vaccination of human immunodeficiency virus (HIV)-1-infected subjects with HIV-1 p17/p24:Ty virus-like particles (p24-VLP) on progression to AIDS, death, a CD4 cell count less than or equal to200 cells/mm(3) and CD4 cell count decline were studied in a multicenter cohort study of 56 individuals who participated in a phase 11 double-blind placebo-controlled trial with p24-VLP in 1993. Using Cox proportional hazard analysis, no difference between vaccine and placebo groups was found in progression to death (adjusted hazard rate (HR): 0.68 (95% Cl: 0.05-7.83), AIDS (adjusted HR: 1.07 (95% CI: 0.21-5.36)) and a CD4 cell count less than or equal to200 cells/mm(3) (adjusted HR: 1.00 (95% Cl: 0.35-2.87)). Using linear regression with correction for multiple visits within one person, no effect of vaccination on CD4 cell count decline, adjusted for antiretroviral therapy (ART) use, was found (P = 0.98). In conclusion, therapeutic vaccination with p24-VLP is not related to slower HIV-1 disease progression. (C) 2002 Elsevier Science Ltd. All rights reserved.